Scientific Advisory Board

The Scientific Advisory Board (SAB) was created in 2002 to provide ongoing, high-level scientific advice to IPM. IPM’s scientific agenda is based on a set of decision-making criteria first approved by the SAB in 2003. The original SAB did not meet regularly, but IPM staff consulted individuals and small groups of IPM members as appropriate to request their expertise in particular areas of microbicide research and/or drug development. IPM established an Executive Committee of its SAB to meet annually, beginning in 2006.

At the 2008 Executive Committee meeting, it was agreed that IPM would restructure the current SAB and its Executive Committee, and reconstitute the membership. Updated Terms of Reference were subsequently determined, as well as new SAB membership. The Executive Committee was dissolved, and as of 2009, the new SAB convenes annually.

IPM’s SAB is composed of members with expertise in drug development, HIV and ARV science, microbicide development, clinical evaluation, delivery system expertise, regulatory knowledge , and other relevant areas. IPM’s Board of Directors review, approve, and update as required the Terms of Reference for the SAB and are consulted on SAB composition and leadership. IPM staff provides SAB members, IPM’s Board of Directors and donors with updates on IPM’s work, including a comprehensive annual report on IPM’s science and product development program and related topics.

	Summary of SAB Meeting - December 2009
	Summary of SAB Executive Committee Meeting - November 2008
	Summary of SAB Executive Committee Meeting - December 2007
	Summary of SAB Executive Committee Meeting - November 2006

Scientific Advisory Board Members

Dr. Robin Shattock, Chair, Professor in Molecular Infection St. George's Hospital Medical School University of London, UK     Dr. Michael Chirenje, Professor Department of Obstetrics and Gynaecology, College of Health Sciences, University of Zimbabwe     Dr. David Friend, Director Product Development, CONRAD, USA     Dr. Sharon Hillier, Principal Investigator, MTN, Co-Principal Investigator Magee-Womens Hospital University of Pittsburgh School of Medicine, USA     Dr. Ruth Merkatz, Director Clinical Development-Reproductive Health, Population Council, USA     Dr. Thomas Moench, Medical Director ReProtect, Inc., USA     Dr. Edith Nakku-Joloba School of Public Health, Makerere University Kampala, Uganda

Dr. Derek Newall, Senior Director Nonclinical Safety Products, GlaxoSmithKline, UK     Dr. Lynn Paxton, Chief Sexual Transmission and Injection Drug Use Studies Section, Centers for Disease Control, USA     Dr. Deenan Pillay, Professor of Virology University College London Medical School, UK     Dr. Renee Ridzon, Epidemiologist, Bill & Melinda Gates Foundation     Dr. Doug Taylor, Director of Biostatistics Family Health International, USA     Dr. Jens Van Roey, Director Global Clinical Development, Tibotec BVBA, Belgium     Dr. Robin Wood, Professor Desmond Tutu Hiv-Research Centre, Faculty of Health Sciences/Medical School, South Africa